Annovis Bio Inc. Advances Phase 3 Alzheimer’s Trial and Reports Q2 2025 Financial Results

Annovis Bio Inc. (NYSE: ANVS), a company at the forefront of developing treatments for neurodegenerative diseases, has reported encouraging progress in its Phase 3 trial for early Alzheimer’s disease, alongside its second-quarter financial results for 2025. The trial, identified as NCT06709014, has now secured 76 U.S. sites, with 46 actively enrolling patients, 38 patients already dosed, and nearly 200 in the screening process. The enrollment is on track, maintaining an expected 50% screen failure rate.

The company has also achieved several key milestones, including the presentation of four scientific posters at AAIC 2025, the appointment of a director of biostatistics, and the hosting of a trial update webcast. Additionally, Annovis Bio has strengthened its intellectual property portfolio by securing global coverage for crystal buntanetap, a significant step in protecting its innovative therapies.

Financially, Annovis Bio reported a positive trajectory with cash and equivalents rising to $17.1 million as of June 30, 2025, up from $10.6 million at the end of 2024. The company also noted a reduction in quarterly R&D expenses to $5.2 million from $5.8 million in the previous year, and a decrease in G&A expenses to $1.1 million from $2.0 million. This financial discipline contributed to a narrowed net loss per share of $0.32, down from $0.44 in the prior-year period.

For more detailed information on Annovis Bio's recent developments and financials, visit https://ibn.fm/iO1TH. The advancements in the Phase 3 Alzheimer’s trial and the improved financial health of the company underscore the potential of Annovis Bio's therapies to make a meaningful difference in the lives of patients suffering from neurodegenerative diseases.